Moreover, there were higher observed co-expression scores for FOXM1/E2F1, FOXA1/GRHL2, FOXA1/GATA3 (Figure 7B), suggesting that absence of FOXA1 might contribute to doxorubicin resistance in breast cancer cells through collaboration with the down-regulated GRHL2 and/or GATA3. Here, FOXA1 is linked to breast carcinoma.